Ok so it’s one of their main earners, the revenue for this drug...

Ok so it’s one of their main earners, the revenue for this drug increased by 4% in one year even with its high cardio toxicity effects. In just over 3 years time their exclusivity for this drug will run out and this will enable other drug companies to produce it and thus under cut them in price. Now along comes RAC with a drug that removes the cardio toxicity issues that this effective drug has. It doesn’t take a brilliant mind to work out that this new combination will be highly successful.
Drug companies make lots of their income by selling their exclusive drugs, sure they will still make money from their old drugs that are not exclusive but not as much. In many cases drug companies will often tweak an old drug a little and claim that the new drug is much better and has less side effects just to enable them to hold exclusivity again for a number of years. I’m thinking
Amgen would want to stitch a deal up pretty quick to avoid a competitor getting a jump on them.